ClinicalTrials.gg
CompletedNCT04078386Updated May 27, 2026

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

A Phase 2 interventional study of Placebo and RC18 240 mg in Primary Sjögren's Syndrome, sponsored by RemeGen Co., Ltd.. Completed at 14 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Primary Sjögren's Syndrome.

02

Conditions studied

  • Primary Sjögren's Syndrome
03

In context

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed ;
  • Patient with primary Sjögren's syndrome according to the European - American consensus group criteria.
  • Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies
  • ESSDAI score ≥ 5.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and other diseases;
  • Abnormal laboratory parameters need to be excluded, including but not limited to:
  • agents were used within 4 weeks prior to randomization.;
  • The use of hydroxychloroquine was allowed during the trial, and the pre-randomized drug regimen was stable for less than 12 weeks;
  • Use of biological agents for targeted therapy in the first 6 months of randomization;
  • Treatment of primary Sjogren's syndrome with traditional Chinese medicine and proprietary Chinese medicine within 4 weeks before randomization;
  • The use of saliva-stimulating drugs within 7 days prior to randomization;
  • Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of the randomized pre-medication scheme is less than 4 weeks;
  • Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before randomization;
  • Infection with herpes zoster or and virus(HCV) antibody positive;
  • Currently suffering from active hepatitis or severe liver lesions and history;
  • Malignant tumor patients ;
  • Combined with involvement of important organs or neuropathy;
  • Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the shorter).
  • Pregnant , lactating women and men or women who have birth plans during the research;
  • Investigator considers candidates not appropriating for the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    RC18 240mg

    Biological: RC18 240 mg

  • Experimental
    RC18 160 mg

    Biological: RC18 160 mg

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalPlacebo

    Patients received the test group Placebo weekly administered subcutaneously for 24 times.

  • BiologicalRC18 240 mg

    Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.

  • BiologicalRC18 160 mg

    Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.

06

What researchers measure

Primary outcomes

  1. The amount of change of European League Against Rheumatism Sjögren's syndrome disease activity(ESSDAI) score compared to the baseline at week 24.

    ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.

    Time frame: week 24

Secondary outcomes

  1. The amount of change of ESSDAI score compared to the baseline at week 12.

    ESSDAI= European League Against Rheumatism Sjögren's syndrome disease activity index score.The ESSDAI includes It includes 12 domains (ie, organ systems: cutaneous,respiratory, renal, articular, muscular,peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular,constitutional,lymphadenopathic,biological).. Each domain is divided into 3-4 levels of activity.The higher the score, the more serious the symptoms ,that is,the worse the results.Subscales are combined by summed.

    Time frame: week 12

  2. The amount of change of European League Against Rheumatism Sjögren'sSyndrome Patient Reported Index(ESSPRI) score compared to the baseline at week 12 and week 24

    European League Against Rheumatism Sjögren's Syndrome Patient Reported Index.Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS. It was suspected that a single 0-10 numerical scale for each domain was sufficient to assess these symptoms.The higher values represent a worse outcome.Subscales are combined by averaged.

    Time frame: week 12,24

  3. Doctors assess overall changes in disease activity relative to baseline at week 12 and week 24

    The measurement tool is Visual Analogue Scale/Score(VAS).The doctor assesses participant's disease activity on a VAS of 0 - 100 mm on the questionnaire form.

    Time frame: week 12,24

  4. Overall patient assessment of disease activity compared to baseline at week 12 and week 24

    The measurement tool is Visual Analogue Scale/Score(VAS). The participant assesses his/her own disease activity on a VAS of 0 - 100 mm on the questionnaire form.

    Time frame: week 12,24

  5. Changes in short form(SF)-36 relative to baseline at week 12 and week 24

    SF-36=36-item short form. As a concise health questionnaire, SF-36 summarized the quality of life of the subjects from eight aspects: physiological function, physical pain, general health condition, energy, social function, emotional function and mental health.The SF-361 is a self-report, 36 item survey measuring health-related quality-of-life. Thirty-five items are used to construct 8 scales. An additional item measures health transition.The higher values represent a better outcome.Subscales are combined by averaged.

    Time frame: week 12,24

  6. Statistical Analysis of the variation of multidimensional fatigue inventory relative to baseline at week 12 and week 24

    Multidimensional Fatigue Inventory.The MFI is a 20-item scale designed to evaluate fi ve dimensions of fatigue: general fatigue, physical fatigue, reduced motivation,reduced activity, and mental fatigue.The higher values represent a worse outcome,Subscales are combined by summed.

    Time frame: week 12,24

07

Study locations

14 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • The First Affiliated Hospital of USTC,Anhui Provincial Hospital
    Hefei, Anhui, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Huzhou Third Municipal Hospital
    Huzhou, Zhejiang, China
  • Beijing Hospital
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • West China School of Medicine,West China Hospital of Sichuan University
    Chengdu, China
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, China
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Tianjin Medical University General Hospital
    Tianjin, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
08

References and documents

Publications

  • Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, Li X, Chen M, Liu X, Liu Y, Li Z, Hu J, Bao C, Wei W, Tian J, Duan X, Zeng X. Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2024 Mar 1;63(3):698-705. doi: 10.1093/rheumatology/kead265. PubMed 37399108 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jun 2021, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2019
First posted
Sep 6, 2019
StartActual
Nov 21, 2019
Primary completionActual
Jun 23, 2021
CompletionActual
Oct 26, 2021
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04078386
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Nov 21, 2019
Primary completion
Jun 23, 2021
Completion
Oct 26, 2021
Last update
May 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion